• 4μ8C: A Translational Lens on IRE1α Biology

  2026-08-26

  4μ8C is more than a selective IRE1α RNase inhibitor: it is a precision tool for separating ER stress signaling from cell-fate outcomes. This thought-leadership analysis connects its use in hypoxic cancer models with new evidence that mono-ADP-ribosylation and ubiquitin-dependent degradation can rapidly reshape stress-responsive transcriptional programs.

• HA-LNP PTEN mRNA for Transdermal Melanoma Immunotherapy

  2026-08-26

  A 2026 Journal of Controlled Release study developed hyaluronate-conjugated lipid nanoparticles containing PTEN mRNA for non-invasive delivery through melanoma-bearing skin. By integrating HA-DMG into the lipid nanoparticle during self-assembly, the platform combined CD44-directed targeting with topical administration, restored PTEN expression, reduced melanoma viability, and enhanced antitumor immune activity in preclinical models.

• Protease Inhibitor Cocktail: MS-Compatible Use

  2026-08-25

  Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue protein extraction while avoiding AEBSF in mass spectrometry workflows. It is not a complete metalloproteinase or phosphatase inhibitor system; EDTA must be evaluated and added separately when metalloproteinase inhibition is required.

• Atorvastatin Workflows for Ferroptosis Research

  2026-08-25

  Atorvastatin is a practical HMG-CoA reductase inhibitor for connecting mevalonate-pathway biology with ferroptosis, vascular signaling, and liver cancer models. This workflow-focused guide covers dosing design, orthogonal validation, solubility control, and interpretation of preclinical findings.

• HA-LNP PTEN mRNA for Transdermal Melanoma Therapy

  2026-08-24

  A 2026 Journal of Controlled Release study developed hyaluronate-conjugated lipid nanoparticles for topical delivery of PTEN mRNA through skin and into melanoma tissue. The platform combined HA-mediated CD44 targeting with localized tumor-suppressor restoration, producing antitumor and immune-activating effects in cellular and mouse models while avoiding an invasive administration route.

• Hoechst 33342: Reliable Nuclear Staining

  2026-08-24

  Learn how Hoechst 33342 (SKU A3472) supports standardized nuclear visualization in live-cell, proliferation, apoptosis, and cytotoxicity workflows. This scenario-based guide covers dye principles, protocol parameters, interpretation limits, and practical vendor-selection criteria.

• Scutellarin, Cathepsin D, and Cardiac I/R Injury

  2026-08-23

  A 2025 Frontiers in Pharmacology study identifies cathepsin D as a mechanistic link between scutellarin treatment and recovery of autophagy-lysosomal function during ischemia/reperfusion injury. Using rat coronary ligation/release and endothelial oxygen-glucose deprivation/reoxygenation models, the researchers show that pharmacological or genetic disruption of cathepsin D eliminates scutellarin-associated vascular and cellular protection.

• Ceruletide as a Mechanistic Probe in Pancreatic Fibrosis

  2026-08-22

  Ceruletide, also known as Caerulein, can do more than induce pancreatic injury: it can help researchers distinguish secretagogue-driven damage from downstream antifibrotic signaling. This article presents a mechanism-oriented framework connecting Ceruletide models with MFGE8-dependent ANXA1-SMAD2/3 biology and regenerative nanomedicine.

• Glucose Uptake Assays in Delivery-Aware Metabolism

  2026-08-22

  Translational glucose biology increasingly depends on connecting metabolic phenotypes with delivery conditions. This thought-leadership guide explains the WST-8 assay mechanism, shows how ion-modulated nucleic acid delivery can shape experimental context, and outlines a rigorous strategy for interpreting cellular glucose uptake data.

• Dovitinib (TKI-258) for Translational Cancer Assays

  2026-08-21

  Dovitinib (TKI-258) connects multitarget RTK inhibition with practical measurements of pathway suppression, viability, and apoptosis. This workflow also shows how radiopathomics concepts can help stratify response phenotypes without mistaking a computational biomarker for direct drug evidence.

• HA-LNP PTEN mRNA for Transdermal Melanoma Therapy

  2026-08-20

  The reference study develops a PEG-free, hyaluronate-integrated lipid nanoparticle for topical delivery of PTEN mRNA into melanoma-bearing skin. Its preclinical results connect localized PTEN restoration with reduced tumor-cell viability, immunogenic cell death, tumor growth suppression, and enhanced antitumor immune activation.

• SB203580 for p38 MAPK Assay Workflows

  2026-08-20

  Learn how to use SB203580 to dissect p38 MAPK-dependent phosphorylation, inflammatory signaling, and stress responses without confusing pathway inhibition with reduced p38 activation. This workflow-centered guide combines concentration planning, orthogonal controls, neuroinflammation applications, and troubleshooting for more interpretable cell-based experiments.

• Leucovorin Calcium for Tumor Assembloid Rescue

  2026-08-19

  A translational framework for using Leucovorin Calcium, or calcium folinate, as a mechanistic rescue control in methotrexate studies, with emphasis on patient-derived gastric cancer assembloids, assay design, resistance biology, and reproducible formulation practices.

• Leucovorin Calcium in Assembloid Rescue Assays

  2026-08-19

  Leucovorin Calcium, also known as calcium folinate, can function as a mechanistic rescue control in methotrexate studies. This guide shows how to use paired gastric cancer organoid and assembloid models to distinguish cell-intrinsic folate sensitivity from microenvironment-dependent drug response.

• Leucovorin Calcium in Tumor Assay Design

  2026-08-18

  Leucovorin Calcium, or calcium folinate, can do more than rescue methotrexate-stressed cells. This article shows how to use folate rescue as a context-sensitive assay control in patient-derived gastric cancer assembloids and interpret stromal effects without overstating the evidence.

7890 records 1/526 page Next 12345 下5页 Last page